Allspring Global Investments Holdings LLC Has $1.68 Million Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Allspring Global Investments Holdings LLC increased its holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 16.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 67,802 shares of the biotechnology company’s stock after purchasing an additional 9,440 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.46% of Anika Therapeutics worth $1,675,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. SG Americas Securities LLC raised its holdings in Anika Therapeutics by 43.1% during the 3rd quarter. SG Americas Securities LLC now owns 9,485 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 2,858 shares during the last quarter. Stonepine Capital Management LLC increased its position in shares of Anika Therapeutics by 171.4% during the second quarter. Stonepine Capital Management LLC now owns 165,397 shares of the biotechnology company’s stock worth $4,190,000 after buying an additional 104,448 shares during the period. Ironwood Investment Management LLC raised its stake in Anika Therapeutics by 109.9% during the second quarter. Ironwood Investment Management LLC now owns 28,704 shares of the biotechnology company’s stock worth $727,000 after buying an additional 15,032 shares during the last quarter. Meros Investment Management LP lifted its holdings in Anika Therapeutics by 25.0% in the second quarter. Meros Investment Management LP now owns 212,714 shares of the biotechnology company’s stock valued at $5,388,000 after buying an additional 42,587 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in Anika Therapeutics by 8.1% in the second quarter. AQR Capital Management LLC now owns 107,373 shares of the biotechnology company’s stock valued at $2,720,000 after buying an additional 8,072 shares during the period. 91.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Barrington Research reiterated an “outperform” rating and set a $37.00 price target on shares of Anika Therapeutics in a report on Tuesday, October 22nd.

Anika Therapeutics Stock Performance

Anika Therapeutics stock opened at $24.68 on Thursday. The stock has a market capitalization of $360.01 million, a price-to-earnings ratio of -4.70 and a beta of 0.83. Anika Therapeutics, Inc. has a 52-week low of $18.83 and a 52-week high of $29.11. The stock’s 50 day moving average price is $24.95 and its two-hundred day moving average price is $25.76.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.24). Anika Therapeutics had a positive return on equity of 0.94% and a negative net margin of 44.45%. The company had revenue of $41.92 million during the quarter, compared to analyst estimates of $39.90 million. During the same quarter in the previous year, the business posted ($0.06) earnings per share. On average, equities research analysts forecast that Anika Therapeutics, Inc. will post -0.1 EPS for the current year.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.